PE20240215A1 - Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo - Google Patents

Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo

Info

Publication number
PE20240215A1
PE20240215A1 PE2023001338A PE2023001338A PE20240215A1 PE 20240215 A1 PE20240215 A1 PE 20240215A1 PE 2023001338 A PE2023001338 A PE 2023001338A PE 2023001338 A PE2023001338 A PE 2023001338A PE 20240215 A1 PE20240215 A1 PE 20240215A1
Authority
PE
Peru
Prior art keywords
peptide
long
composition
acting conjugate
group
Prior art date
Application number
PE2023001338A
Other languages
English (en)
Inventor
Jung Kuk Kim
Young Jin Park
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of PE20240215A1 publication Critical patent/PE20240215A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica que comprende i) un peptido que comprende la secuencia de aminoacidos seleccionada del grupo que consiste en SEQ ID NOs: 13, 15 y 36 a 44, (derivado de glucagon) y ii) al menos un compuesto o material que se selecciona del grupo que consiste en un peptido insulinotropico, un agonista del receptor del peptido 1 similar al glucagon-1 (GLP-1), un agonista del receptor de leptina, entre otros. Ademas, el peptido i) puede encontrarse en forma de un conjugado de accion prolongada, a la que esta unido un material biocompatible y el peptido insulinotropico ii) puede encontrarse en forma de un conjugado de accion prolongada, al que esta unido un material biocompatible, donde el material biocompatible se selecciona del grupo que consiste en polietilenglicol, acido graso, colesterol, un material de union a FcRn entre otros. Dicha composicion puede ser util en el tratamiento o la prevencion del sindrome metabolico.
PE2023001338A 2015-06-30 2016-06-29 Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo PE20240215A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30
PCT/KR2016/006984 WO2017003191A1 (en) 2015-06-30 2016-06-29 Glucagon derivative and a composition comprising a long acting conjugate of the same

Publications (1)

Publication Number Publication Date
PE20240215A1 true PE20240215A1 (es) 2024-02-16

Family

ID=57608802

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023001338A PE20240215A1 (es) 2015-06-30 2016-06-29 Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
PE2017002855A PE20180449A1 (es) 2015-06-30 2016-06-29 Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017002855A PE20180449A1 (es) 2015-06-30 2016-06-29 Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo

Country Status (30)

Country Link
US (3) US10696725B2 (es)
EP (2) EP4324519A2 (es)
JP (3) JP6882210B2 (es)
KR (2) KR102005456B1 (es)
CN (1) CN108025041A (es)
AR (1) AR105485A1 (es)
AU (2) AU2016287209B2 (es)
BR (1) BR112017028517A2 (es)
CA (1) CA2991107A1 (es)
CL (5) CL2017003402A1 (es)
CO (1) CO2018000303A2 (es)
CR (1) CR20180034A (es)
DK (1) DK3322437T3 (es)
DO (1) DOP2017000318A (es)
EA (1) EA201890058A1 (es)
EC (1) ECSP18003879A (es)
FI (1) FI3322437T3 (es)
HK (1) HK1248129A1 (es)
IL (2) IL256619B (es)
MA (2) MA49545B1 (es)
MX (1) MX2017016845A (es)
NZ (1) NZ739250A (es)
PE (2) PE20240215A1 (es)
PH (1) PH12017502393A1 (es)
PT (1) PT3322437T (es)
TN (1) TN2017000555A1 (es)
TW (1) TWI713541B (es)
UA (1) UA127445C2 (es)
UY (1) UY36759A (es)
WO (1) WO2017003191A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2016108586A1 (ko) * 2014-12-30 2016-07-07 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
PE20240215A1 (es) 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
TN2018000231A1 (en) 2015-12-31 2019-10-04 Hanmi Pharm Ind Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EP3479841A4 (en) * 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION COMPRISING SAME, AND THERAPEUTIC USE THEREOF
JP2020506932A (ja) 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
JP7121024B2 (ja) 2017-02-07 2022-08-17 ハンミ ファーマシューティカルズ カンパニー リミテッド 非ペプチド性重合体リンカー化合物、そのリンカー化合物を含む結合体、及びそれらの製造方法
EP3689914A4 (en) * 2017-09-29 2021-08-25 Hanmi Pharm. Co., Ltd. PERSISTENT PROTEIN CONJUGATE WITH IMPROVED EFFICIENCY
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
CN112912095A (zh) 2018-07-19 2021-06-04 D&D制药技术股份有限公司 包括多肽的药物组合物
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
KR20200038878A (ko) * 2018-10-04 2020-04-14 한미약품 주식회사 글루카곤 및 이를 포함하는 조합물의 치료학적 용도
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
EP3900734A4 (en) * 2018-12-21 2022-10-12 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION WITH INSULIN AND GLUCAGON
JP7111917B2 (ja) * 2019-06-28 2022-08-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用
US20230000950A1 (en) * 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
US20210290732A1 (en) * 2020-02-21 2021-09-23 Spitfire Pharma Llc GLP-1R and GCGR Agonists, Formulations, and Methods of Use
BR112022023618A2 (pt) 2020-05-22 2023-02-07 Hanmi Pharm Ind Co Ltd Formulação líquida de conjugado de ação prolongada de derivado de glucagon
EP4183407A1 (en) 2020-07-15 2023-05-24 Hanmi Pharm. Co., Ltd. Therapeutic use of glucagon derivative or conjugate thereof for liver disease
MX2023001601A (es) * 2020-08-14 2023-03-07 Hanmi Pharmaceutical Co Ltd Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
KR20220140443A (ko) 2021-04-09 2022-10-18 한미약품 주식회사 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
MXPA05009940A (es) 2003-03-19 2005-12-05 Lilly Co Eli Compuestos de glp-1 de enlace de glicol polietilenico.
ES2372495T3 (es) * 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
CN102015761A (zh) 2007-06-19 2011-04-13 大塚化学株式会社 附加糖链的glp-1肽
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
MX2010012695A (es) * 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6054742B2 (ja) * 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EA026384B1 (ru) 2010-01-20 2017-04-28 Зилэнд Фарма А/С Лечение заболеваний сердца
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
JP6284471B2 (ja) 2011-05-18 2018-02-28 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチドの調合薬
DK2718318T3 (en) * 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
WO2012173422A1 (en) 2011-06-17 2012-12-20 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
JP6396211B2 (ja) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
US20150005233A1 (en) 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
CN107739409A (zh) 2012-05-18 2018-02-27 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
BR112014031671A2 (pt) 2012-06-21 2018-08-07 Hoffmann La Roche análogos de glucagon exibindo atividade de receptor gip
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA034499B1 (ru) 2012-11-06 2020-02-13 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
CN104918961A (zh) 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
KR20150096433A (ko) 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
CN107106680A (zh) * 2014-11-13 2017-08-29 江苏奥赛康药业股份有限公司 具备双受体激动剂活性的融合蛋白
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016108586A1 (ko) * 2014-12-30 2016-07-07 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
PE20240215A1 (es) 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
EP3384935A4 (en) 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME
TN2018000231A1 (en) 2015-12-31 2019-10-04 Hanmi Pharm Ind Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist

Also Published As

Publication number Publication date
IL291291A (en) 2022-05-01
CL2023001910A1 (es) 2023-11-17
EP3322437B1 (en) 2024-01-17
CL2023001911A1 (es) 2023-11-17
TN2017000555A1 (en) 2019-04-12
AU2016287209B2 (en) 2023-03-02
EA201890058A1 (ru) 2018-07-31
EP3322437A1 (en) 2018-05-23
IL256619B (en) 2022-04-01
KR20170003466A (ko) 2017-01-09
TWI713541B (zh) 2020-12-21
AR105485A1 (es) 2017-10-11
HK1248129A1 (zh) 2018-10-12
MX2017016845A (es) 2018-08-01
JP2018526333A (ja) 2018-09-13
US20200223897A1 (en) 2020-07-16
JP6882210B2 (ja) 2021-06-02
FI3322437T3 (fi) 2024-02-20
PH12017502393A1 (en) 2018-06-25
KR102005456B1 (ko) 2019-07-30
CL2017003402A1 (es) 2018-04-20
IL256619A (en) 2018-04-30
EP4324519A2 (en) 2024-02-21
JP2021102618A (ja) 2021-07-15
CO2018000303A2 (es) 2018-07-10
US20180186853A1 (en) 2018-07-05
CR20180034A (es) 2018-04-16
ECSP18003879A (es) 2018-03-31
US20220127325A1 (en) 2022-04-28
CN108025041A (zh) 2018-05-11
UA127445C2 (uk) 2023-08-30
WO2017003191A1 (en) 2017-01-05
NZ739250A (en) 2024-02-23
MA49545B1 (fr) 2022-03-31
CL2023001909A1 (es) 2023-11-17
UY36759A (es) 2017-01-31
DOP2017000318A (es) 2018-04-30
AU2016287209A1 (en) 2018-02-15
MA41887B1 (fr) 2020-05-29
US11261227B2 (en) 2022-03-01
DK3322437T3 (da) 2024-03-25
US10696725B2 (en) 2020-06-30
KR20190092343A (ko) 2019-08-07
KR102395855B1 (ko) 2022-05-10
PT3322437T (pt) 2024-03-20
TW201713681A (zh) 2017-04-16
BR112017028517A2 (pt) 2018-08-28
IL291291B2 (en) 2023-06-01
PE20180449A1 (es) 2018-03-05
AU2023201118A1 (en) 2023-04-20
US11667688B2 (en) 2023-06-06
EP3322437A4 (en) 2019-10-09
CA2991107A1 (en) 2017-01-05
JP2023062043A (ja) 2023-05-02
MA49545A1 (fr) 2021-09-30
CL2023000198A1 (es) 2023-06-30
MA41887A1 (fr) 2018-12-31

Similar Documents

Publication Publication Date Title
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
ECSP17084280A (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
PE20220938A1 (es) Compuestos agonistas de gipr
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
AR092873A1 (es) Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
PE20140724A1 (es) Coagonistas del receptor de glucagon/glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
PE20140795A1 (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada
PE20211417A1 (es) Analogos novedosos de glp-1
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
EP4272823A3 (en) Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor agonist
EA200800181A1 (ru) Фармацевтическая композиция glp-1
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2017008505A (es) Composicion.